A trio of high-octane income stocks -- sporting an average yield of 6.65% -- can fatten investors' pocketbooks in 2025 (and ...

In the last reported quarter, the company delivered an earnings surprise of 65.62%, as seen in the chart below. Pfizer has an ... for the COVID-19 vaccine, Comirnaty, and product revenues from ...

PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the fourth quarter.

Three years ago in April, Jamie suffered a catastrophic bleed on the brain after being given the AstraZeneca Covid vaccine.

Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4 ...

Looking at options history for Pfizer ... covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account ...

Although COVID ... vaccine. "We know other countries didn't think Australia had a problem, so we probably weren't a priority," she said. "There was at least one case, I think it was with Pfizer ...

Maze Therapeutics became the latest drug developer to list in New York on Friday, with its shares rising nearly 1% in their debut, giving the company a valuation of $690.37 million.

Unexpected demand for Pfizer Inc.’s Covid vaccine helped the company beat quarterly expectations. Then Robert F. Kennedy Jr., ...

Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...